查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1510485

人性化小鼠模型市場 - 全球產業規模、佔有率、趨勢、機會和預測，按類型、應用、最終用戶、地區和競爭細分，2019-2029F

Humanized Mice Model Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Application, By End User, By Region and Competition, 2019-2029F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2023 年全球人源化小鼠模型市場估值為11.5 億美元，預計在預測期內將強勁成長，到2029 年複合年成長率為9.80%。基因工程改造的小鼠會表達人類基因。這些小鼠廣泛用於闡明和理解人類生理學和人類特異性感染的病因。人源化小鼠由於具有體積小、繁殖週期短、易於處理以及與人類基因組相似性增加等眾多優點，在人類學開發的生物醫學研究中發揮著至關重要的作用。這些模型是臨床前研究的關鍵工具，因為它們可以模擬幾種人類特異性疾病，並能夠研究免疫療法的有效性和安全性。值得注意的是，人源化小鼠模型對 COVID-19 疫苗和抗體療法的設計和開發做出了重大貢獻。自從冠狀病毒感染爆發以來，這些模型有望對感染、抗病毒治療的有效性提供更深入、更全面的了解，並支持開發治療這種疾病的有效藥物和療法。預計這種趨勢將持續下去，促進市場收入的成長。

市場概況
預測期 2025-2029
2023 年市場規模 11.5億美元
2029 年市場規模 20.1億美元
2024-2029 年複合年成長率 9. 80%
成長最快的細分市場 腫瘤學
最大的市場 北美洲

主要市場促進因素

對個人化醫療的需求不斷增加

基因編輯工具的進步

增加小鼠模型的創新

製藥和生物製藥公司的產品線不斷成長

主要市場挑戰

與人源化小鼠模型開發相關的高成本

道德使用動物的規定

主要市場趨勢

增加小鼠模型的創新

基因組學、蛋白質組學和代謝組學的進展

細分市場洞察

應用洞察

區域洞察

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：客戶之聲

第 5 章：全球人源化小鼠模型市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依類型（人源化小鼠模型、人源化大鼠模型）
    • 按應用（腫瘤學、免疫學和傳染病、毒理學、其他）
    • 按最終用戶（製藥和生物技術公司、合約研究組織、學術和研究機構）
    • 按地區
    • 按公司分類 (2023)
  • 市場地圖

第 6 章：北美人源化小鼠模型市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按申請
    • 按最終用戶
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第 7 章：歐洲人性化小鼠模型市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按申請
    • 按最終用戶
    • 按國家/地區
  • 歐洲：國家分析
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙

第 8 章：亞太地區人源化小鼠模型市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按申請
    • 按最終用戶
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第 9 章：南美洲人源化小鼠模型市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按申請
    • 按最終用戶
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲人性化小鼠模型市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按申請
    • 按最終用戶
    • 按國家/地區
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 促進要素
  • 挑戰

第 12 章：市場趨勢與發展

  • 併購（如有）
  • 產品發布（如有）
  • 最近的發展

第 13 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第14章：競爭格局

  • Allentown LLC
  • Charles River Laboratories International, Inc.
  • HBM Holdings
  • Horizon Discovery Group plc
  • Ingenious Targeting Laboratory Inc.
  • Janvier Labs
  • Trans Genic Inc.
  • PolyGene AG
  • Aragen Life Sciences Ltd.
  • The Andersons, Inc.

第 15 章：策略建議

第16章調查會社について,免責事項

簡介目錄
Product Code: 4827

Global Humanized Mice Model Market was valued at USD 1.15 Billion in 2023 and is anticipated to project robust growth in the forecast period with a CAGR of 9.80% through 2029. Humanized mice models are mice that have undergone xenotransplantation with human cells or have been genetically engineered to express human genes. These mice are extensively utilized in elucidating and comprehending human physiology and the etiology of human-specific infections. Humanized mice play a crucial role in biomedical research for the development of human therapeutics, owing to their numerous advantages such as small size, short reproductive cycle, ease of handling, and increased genomic similarity to humans. These models serve as critical tools in preclinical research studies, as they can mimic several human-specific diseases and enable the study of immunotherapy approaches' efficacy and safety. Notably, humanized mice models have significantly contributed to the design and development of vaccines and antibody-based therapies for COVID-19. Since the outbreak of coronavirus infection, these models are expected to provide a deeper and more comprehensive understanding of the infection, the effectiveness of antiviral therapeutics, and support the development of efficient drugs and therapies for the treatment of this disease. It is anticipated that this trend will continue, contributing to the revenue growth of the market.

Market Overview
Forecast Period2025-2029
Market Size 2023USD 1.15 Billion
Market Size 2029USD 2.01 Billion
CAGR 2024-20299. 80%
Fastest Growing SegmentOncology
Largest MarketNorth America

Key Market Drivers

Increasing Need for Personalized Medicine

Precision or personalized medicine is a groundbreaking and transformative approach that revolutionizes the healthcare industry. It focuses on creating tailored medications and therapeutic strategies that address the individual complexity and genetic variations of patients in a highly precise manner. By utilizing advanced techniques, such as next-generation sequencing and high-throughput screening, researchers can gain a comprehensive understanding of the genetic makeup of patients and identify specific molecular targets for treatment. One significant aspect of precision medicine is the development and utilization of mice models, particularly immunodeficient mice models that can express human-specific pathologies. These models enable researchers to mimic human diseases and study their mechanisms in a controlled environment. By investigating the underlying molecular mechanisms of diseases, researchers can identify potential targets for drug development and gene therapies.

Precision medicine goes beyond a one-size-fits-all approach by tailoring treatment options to suit each patient's unique needs. By analyzing an individual's genetic profile, lifestyle factors, and environmental influences, healthcare providers can determine the most suitable treatment options for optimizing patient outcomes. This personalized approach holds great promise in transforming the way we diagnose, treat, and manage diseases, ultimately improving the quality of life for patients worldwide. The potential of precision medicine to revolutionize healthcare is expected to drive significant revenue growth in the market over the forecast period. With ongoing advancements in technology and research, precision medicine will continue to provide personalized solutions that enhance patient care and lead to better health outcomes. By embracing this innovative approach, we can unlock new possibilities in the field of medicine and pave the way for a healthier future.

Advancement In Gene Editing Tools

The advent of advanced gene editing tools, such as CRISPR/Cas9 technology, have revolutionized the field of biomedical research. With these powerful tools at our disposal, scientists have been able to accelerate the development of mutant and genetically engineered mice, enabling them to study the intricate characteristics of various diseases in more depth than ever before. This breakthrough technology is not only expected to significantly contribute to the advancement of scientific knowledge but also holds the potential to drive substantial revenue growth in the market moving forward. By providing researchers with precise and efficient genome editing capabilities, CRISPR/Cas9 has opened up new possibilities for targeted gene therapies and personalized medicine. Its potential impact ranges from treating genetic diseases to improving crop production and environmental conservation.

The ability to precisely edit DNA sequences has unlocked a wealth of opportunities for biomedical research and biotechnology, with implications that extend far beyond the laboratory. As the technology continues to evolve and be refined, we can anticipate even more exciting breakthroughs in the field of gene editing. The ongoing advancements in CRISPR/Cas9 and related tools promise to revolutionize not only how we understand and treat diseases but also how we shape the world around us. The future of biomedical research and its potential for transformative impact has never been more promising.

Increasing Innovation in Mice Models

The drive to enhance biomedical research and drug development has ignited a rapid evolution in the realm of mice models, with a particular emphasis on humanized mice. These innovative models, genetically modified to incorporate human genes, tissues, or immune systems, hold immense promise in mirroring human physiological responses and disease pathways more accurately than conventional animal models. As scientific understanding becomes increasingly intricate, the demand for sophisticated tools that can faithfully recapitulate human conditions surges. This is where humanized mice models come to the fore. By offering a platform to simulate human-specific diseases, evaluate novel therapies, and unravel complex immune interactions, these models stand as invaluable assets in modern medical research.

The prospect of advancing innovation in mice models translates to a cascade of benefits, propelling the demand for humanized mice models. Researchers are presented with an unparalleled opportunity to delve into the intricacies of human biology, conduct safer and more efficient preclinical drug trials, and personalize treatment strategies. This heightened demand resonates across various fields, from oncology and immunology to infectious diseases, as scientists recognize the potential to bridge the gap between bench and bedside. Pharmaceutical and biotechnology industries keen on expediting drug discovery and development find in humanized mice models a potent catalyst for success.

Growing Pipeline of Pharmaceutical & Biopharmaceutical Companies

The growing pipeline of pharmaceutical and biopharmaceutical companies is poised to usher in a significant surge in the demand for humanized mice models. This heightened demand can be attributed to the increasingly complex landscape of drug development, where precision and predictive models are indispensable. Humanized mice models, genetically engineered to incorporate human genes, immune systems, or tissues, offer a remarkable platform for assessing drug efficacy, safety, and toxicity with a level of accuracy that traditional animal models cannot match. The demand for humanized mice models is amplified by the imperative to address a diverse range of therapeutic areas, from oncology and immunology to infectious diseases and regenerative medicine. As these industries grow, so does the necessity for reliable and versatile preclinical models that can bridge the translational gap between the laboratory and clinical trials.

The burgeoning pipeline of pharmaceutical and biopharmaceutical companies is driving a robust demand for humanized mice models. These models are the linchpin in modern drug development efforts, offering the precision and fidelity required to navigate the intricacies of human biology and disease. As the pharmaceutical and biopharmaceutical sectors continue to expand and evolve, humanized mice models are destined to play an increasingly pivotal role in advancing drug discovery and ultimately improving patient outcomes.

Key Market Challenges

High costs Associated with Development of Humanized Mice Models

Humanized mice models, a cutting-edge approach in biomedical research, involve the grafting of human tissues, genes, and cells into immunodeficient mice. While these models hold great promise in advancing our understanding of human diseases and developing novel therapies, their widespread adoption has been limited due to the substantial expenses associated with their production and maintenance. This financial burden has hindered the global expansion of humanized mice models, placing a certain degree of constraint on market growth in the foreseeable future.

The utilization of animal models in experiments and preclinical studies is subject to stringent regulatory frameworks. These regulations aim to ensure ethical treatment and minimize animal suffering, but they also pose challenges to the broader implementation of humanized mice models. As a result, market growth in this field is expected to face significant hurdles in the coming years. Despite these obstacles, ongoing advancements in technology and increasing efforts to refine animal research practices offer glimpses of hope. With continued innovation and collaboration, the potential of humanized mice models can be fully realized, paving the way for groundbreaking discoveries and transformative medical interventions.

Regulations for the Ethical Use of Animals

The demand for humanized mice models is set to experience a significant uptick due to the increasingly stringent regulations governing the ethical use of animals in research. In response to growing concerns about animal welfare and ethical considerations, regulatory authorities around the world have been implementing and reinforcing guidelines aimed at minimizing the use of traditional animal models. This shift towards more ethical research practices has led to a heightened interest in humanized mice models as a viable alternative.

This growing emphasis on ethical research practices, combined with an increasing awareness of the limitations and ethical concerns associated with traditional animal models, is propelling the demand for humanized mice models. These models not only satisfy regulatory requirements but also offer researchers a more accurate and human-relevant platform for preclinical testing and drug development. As a result, pharmaceutical companies, biotechnology firms, and academic institutions are increasingly turning to humanized mice models as a responsible and ethical choice, ultimately contributing to a more compassionate and responsible approach to biomedical research.

Key Market Trends

Increasing Innovation in Mice Models

The increasing innovation in mice models is poised to have a transformative impact on the future of biomedical research, significantly driving up the demand for these models. Mice have long served as a cornerstone of preclinical research due to their genetic similarity to humans and relatively short breeding cycles. However, recent advancements in genetic engineering, genome editing, and model development techniques are expanding the possibilities and applications of mice models in unprecedented ways. Innovations in mice models extend beyond genetic modifications. Advanced techniques like the generation of humanized mice, where human cells, tissues, or organs are incorporated, have opened new frontiers in the study of human-specific diseases, immune responses, and personalized medicine. The ability to simulate intricate aspects of human biology within a living organism is revolutionizing drug testing and therapeutic development, attracting substantial interest from researchers across various fields.

The increasing innovation in mice models is driving an upsurge in demand, promising a future where these models will play an even more pivotal role in biomedical research and drug discovery. As scientific understanding deepens and technologies continue to evolve, mice models are positioned to remain at the forefront of cutting-edge research, ultimately contributing to groundbreaking discoveries and improved healthcare outcomes for the future.

Progress In Genomics, Proteomics, And Metabolomics

The increasing innovation in mice models is poised to have a transformative impact on the future of biomedical research, significantly driving up the demand for these models. Mice have long served as a cornerstone of preclinical research due to their genetic similarity to humans and relatively short breeding cycles. However, recent advancements in genetic engineering, genome editing, and model development techniques are expanding the possibilities and applications of mice models in unprecedented ways.

Innovations in mice models extend beyond genetic modifications. Advanced techniques like the generation of humanized mice, where human cells, tissues, or organs are incorporated, have opened new frontiers in the study of human-specific diseases, immune responses, and personalized medicine. The ability to simulate intricate aspects of human biology within a living organism is revolutionizing drug testing and therapeutic development, attracting substantial interest from researchers across various fields.

Segmental Insights

Application Insights

Based on application, the global humanized mice model market has been segmented into oncology, immunology & infectious diseases, toxicology, and others. Within the oncology segment, it is anticipated that there will be a substantial increase in revenue CAGR over the forecast period. This can be attributed to the rising prevalence of cancer worldwide, along with the growing focus on cancer research and development activities. There is an increasing need to address unmet clinical demands, which further drives the demand for humanized mice models in oncology research. Humanized mice models offer a more realistic and comprehensive approach to studying tumour biology compared to traditional methods such as cultured cancer cells. This enhanced realism not only facilitates a better understanding of tumour growth and progression but also enables researchers to evaluate the efficacy of various therapeutic interventions. As a result, the adoption of humanized mice models in oncology research is expected to contribute significantly to the growth of the market over the forecast period.

Regional Insights

North America is projected to hold the largest market share in terms of revenue over the forecast period. This growth can be attributed to the increasing research activities in the pharmaceutical and biotechnology sectors in the United States, the growing biopharmaceutical industry, the rising demand and production of monoclonal antibodies, and advancements in protein therapeutics. The region is expected to witness revenue growth due to the growing number of preclinical and clinical activities by Contract Research Organizations (CROs), rapid progress in stem cell research, and increased government support.

In the Asia Pacific region, a robust revenue Compound Annual Growth Rate (CAGR) is anticipated during the forecast period. This can be attributed to the rapid growth of the biomedical sector, advancements in translational research, and the increasing demand for precision medicine in countries such as India, China, Japan, and other APAC countries. Notably, China is expected to hold the largest revenue share in the Asia Pacific market due to the increasing animal research, mandatory animal testing for pharmaceutical drugs and cosmetics, the growing biomedical sector, and the rapid rise in strategic alliances between research institutes in China and international institutes and companies. Factors such as the availability of a massive target patient pool, low cost of clinical trials, and lenient regulatory approvals are also expected to contribute to the revenue growth of the market in the region.

Key Market Players

Allentown LLC

Charles River Laboratories International, Inc.

HBM Holdings

Horizon Discovery Group plc

Ingenious Targeting Laboratory Inc.

Janvier Labs

Trans Genic Inc.

PolyGene AG

Aragen Life Sciences Ltd.

The Andersons, Inc.

Report Scope:

In this report, the Global Humanized Mice Model Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Humanized Mice Model Market, By Type:

    Humanized Mouse Models Humanized Rat Models

Humanized Mice Model Market, By Application:

    Oncology Immunology & Infectious Diseases Toxicology Others

Humanized Mice Model Market, By End User:

    Pharmaceutical & Biotechnology Companies Contract Research Organizations Academic & Research Institutions

Humanized Mice Model Market, By Region:

    North America
    • United States
    • Canada
    • Mexico
    Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
    Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    South America
    • Brazil
    • Argentina
    • Colombia
    Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Humanized Mice Model Market.

Available Customizations:

Global Humanized Mice Model market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validations
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Humanized Mice Model Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Humanized Mouse Models, Humanized Rat Models)
    • 5.2.2. By Application (Oncology, Immunology & Infectious Diseases, Toxicology, Others)
    • 5.2.3. By End User (Pharmaceutical & Biotechnology Companies, Contract Research Organizations, Academic & Research Institutions)
    • 5.2.4. By Region
    • 5.2.5. By Company (2023)
  • 5.3. Market Map

6. North America Humanized Mice Model Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Application
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Humanized Mice Model Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By End User
    • 6.3.2. Canada Humanized Mice Model Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By End User
    • 6.3.3. Mexico Humanized Mice Model Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By End User

7. Europe Humanized Mice Model Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Application
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Humanized Mice Model Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By End User
    • 7.3.2. United Kingdom Humanized Mice Model Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By End User
    • 7.3.3. Italy Humanized Mice Model Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecasty
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By End User
    • 7.3.4. France Humanized Mice Model Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Humanized Mice Model Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By End User

8. Asia-Pacific Humanized Mice Model Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Application
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Humanized Mice Model Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By End User
    • 8.3.2. India Humanized Mice Model Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By End User
    • 8.3.3. Japan Humanized Mice Model Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By End User
    • 8.3.4. South Korea Humanized Mice Model Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Humanized Mice Model Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By End User

9. South America Humanized Mice Model Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Application
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Humanized Mice Model Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By End User
    • 9.3.2. Argentina Humanized Mice Model Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By End User
    • 9.3.3. Colombia Humanized Mice Model Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By End User

10. Middle East and Africa Humanized Mice Model Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Application
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Humanized Mice Model Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By End User
    • 10.3.2. Saudi Arabia Humanized Mice Model Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By End User
    • 10.3.3. UAE Humanized Mice Model Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Porters Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

  • 14.1. Allentown LLC
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As Reported)
    • 14.1.5. Recent Developments
    • 14.1.6. Key Personnel Details
    • 14.1.7. SWOT Analysis
  • 14.2. Charles River Laboratories International, Inc.
  • 14.3. HBM Holdings
  • 14.4. Horizon Discovery Group plc
  • 14.5. Ingenious Targeting Laboratory Inc.
  • 14.6. Janvier Labs
  • 14.7. Trans Genic Inc.
  • 14.8. PolyGene AG
  • 14.9. Aragen Life Sciences Ltd.
  • 14.10. The Andersons, Inc.

15. Strategic Recommendations

16. About Us & Disclaimer